Your browser doesn't support javascript.
Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019.
Kim, Ji-Won; Kwak, Sang Gyu; Lee, Hwajeong; Kim, Seong-Kyu; Choe, Jung-Yoon; Park, Sung-Hoon.
  • Kim JW; Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
  • Kwak SG; Department of Medical Statistics, Daegu Catholic University School of Medicine, Daegu, Korea.
  • Lee H; Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
  • Kim SK; Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
  • Choe JY; Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
  • Park SH; Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Korean J Intern Med ; 37(3): 673-680, 2022 05.
Article in English | MEDLINE | ID: covidwho-1737116
ABSTRACT
BACKGROUND/

AIMS:

The preventive role of hydroxychloroquine (HCQ) on coronavirus disease 2019 (COVID-19) remains unclear. The aim of this study was to examine the effects of HCQ and other immunosuppressive drugs on the incidence of COVID-19.

METHODS:

The data were collected from the South Korea National Health Insurance Sharing-COVID-19 database. All individuals who underwent nasopharyngeal and oropharyngeal swab tests for COVID-19 from January 2020 to May 2020 are included. The association between COVID-19 risk and HCQ use was examined in a propensity score-matched population. Factors associated with COVID-19 were identified using multiple logistic regression analysis.

RESULTS:

Total 8,070 patients with COVID-19 and 121,050 negative controls were included from the database. Among all participants, 381 were HCQ users. In a propensity score-matched population, the incidence of COVID-19 was 7.1% in HCQ users and 6.8% in non-users. The odds ratio (OR) for HCQ use was 1.05 with a 95% confidence interval (CI) of 0.58 to 1.89. Among the subpopulation of patients with rheumatoid arthritis (RA), 33 were diagnosed with COVID-19 and 478 were not. Use of HCQ, glucocorticoids, or other immunosuppressive drugs was not associated with COVID-19 risk, whereas abatacept use was. Chronic lung disease was an independent risk factor for COVID-19 diagnosis in patients with RA (adjusted OR, 6.07; 95% CI, 1.10 to 33.59).

CONCLUSION:

The risk of COVID-19 did not differ between HCQ users and non-users. Glucocorticoids, conventional disease-modifying antirheumatic drugs (DMARDs), and biological DMARDs other than abatacept did not increase the risk of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / COVID-19 / COVID-19 Drug Treatment Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Korean J Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / COVID-19 / COVID-19 Drug Treatment Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: Korean J Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article